In the Covid-19 and influenza combo vaccine race, Pfizer and BioNTech reported a hiccup on Friday with uneven results in a Phase 3 test.
The companies’ Covid-flu vaccine didn’t meet the Phase 3 primary endpoint of non-inferior immunogenicity against influenza, in comparison with people who received separate Covid and flu vaccines. While the combo vaccine elicited a “robust” response against influenza A, it delivered lower geometric mean titers and seroconversion versus influenza B.
The combo vaccine did however meet the other primary endpoint of non-inferior immunogenicity against SARS-CoV-2 versus the companies’ marketed Covid vaccine Comirnaty. The study enrolled more than 8,000 adults aged 18 to 64 years old.
Pfizer’s head of vaccine research Annaliesa Anderson said in a statement that the company is “evaluating next steps” for the combined vaccine. The company has plans to potentially make tweaks to improve how it responds to influenza B and also meet with
